<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, remdesivir is only approved in Japan for patients with SARS-CoV-2 infection. Outside Japan, it is still an investigational drug. The US-FDA has granted remdesivir “emergency use authorization” on May 1, 2020, for treatment of suspected or microbiologically confirmed hospitalized patients with severe COVID-19.
 <sup>
  <xref rid="B16" ref-type="bibr">16</xref>
 </sup> This authorization is temporary.
</p>
